Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19
复制标题
DOI：
10.1016/j.jacc.2020.08.041
复制
发表时间：
2020-10-20
影响因子：
24
通讯作者：
Fuster, Valentin
中科院分区：
文献类型：
--
作者：
Nadkarni, Girish N.;Lala, Anuradha;Fuster, Valentin
背景血栓栓塞病是冠状病毒病中常见的疾病-2019年(新冠肺炎)。关于院内抗凝(AC)与预后和尸检结果之间的相关性的证据有限。目的：本研究的目的是探讨院内抗凝与院内结局的关系，并描述尸检中血栓栓塞症的发现。方法本研究回顾分析了AC与死亡率、插管和大出血之间的关系。此外，还对治疗性AC与预防性AC之间的关系进行了子分析
BACKGROUND Thromboembolic disease is common in coronavirus disease-2019 (COVID-19). There is limited evidence on the association of in-hospital anticoagulation (AC) with outcomes and postmortem findings.OBJECTIVES The purpose of this study was to examine association of AC with in-hospital outcomes and describe thromboembolic findings on autopsies.METHODS This retrospective analysis examined the association of AC with mortality, intubation, and major bleeding. Subanalyses were also conducted on the association of therapeutic versus prophylactic AC initiated